Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model

Biochemical and Biophysical Research Communications

Volumn 379, Issue 2, 2009, Pages 406-410

  Escribano, Luis ^a   Simón, Ana María ^a   Pérez Mediavilla, Alberto ^a   Salazar Colocho, Pablo ^a   Río, Joaquín Del ^a   Frechilla, Diana ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Alzheimer's disease; Glucocorticoids; Hippocampus; Memory; Peroxisome proliferator activated receptor

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CORTICOSTERONE; GLUCOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DISEASE MODEL; DRUG POTENCY; GENE OVEREXPRESSION; LIGAND BINDING; MEMORY DISORDER; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DOWN-REGULATION; HIPPOCAMPUS; HUMANS; MEMORY DISORDERS; MICE; MICE, TRANSGENIC; PPAR GAMMA; RECEPTORS, GLUCOCORTICOID; THIAZOLIDINEDIONES;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 58149485983     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.071     Document Type: Article

References (30)

1. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
2. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
3. Biessels G.J., and Kappelle L.J. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochem. Soc. Trans. 33 (2005) 1041-1044
4. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
5. Heneka M.T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F., and Landreth G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta 1-42 levels in APPV717I transgenic mice. Brain 128 (2005) 1442-1453
6. Pedersen W.A., McMillan P.J., Kulstad J.J., Leverenz J.B., Craft S., and Haynatzki G.R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199 (2006) 265-273
7. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G.E., Walter J., Klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA 103 (2006) 443-448
8. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., and Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 28 (2008) 9287-9296
9. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., and Roses A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6 (2006) 246-254
10. Watson G.S., Cholerton B.A., Reger M.A., Baker L.D., Plymate S.R., Asthana S., Fishel M.A., Kulstad J.J., Green P.S., Cook D.G., Kahn S.E., Keeling M.L., and Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13 (2005) 950-958
11. Sastre M., Dewachter I., Landreth G.E., Willson T.M., Klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23 (2003) 9796-9804
12. Camacho I.E., Serneels L., Spittaels K., Merchiers P., Dominguez D., and De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24 (2004) 10908-10917
13. d'Abramo C., Massone S., Zingg J.M., Pizzuti A., Marambaud P., Dalla Piccola B., Azzi A., Marinari U.M., Pronzato M.A., and Ricciarelli R. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem. J. 391 (2005) 693-698
14. Strum J.C., Shehee R., Virley D., Richardson J., Mattie M., Selley P., Ghosh S., Nock C., Saunders A., and Roses A. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis. 11 (2007) 45-51
15. Elgh E., Lindqvist Astot A., Fagerlund M., Eriksson S., Olsson T., and Nasman B. Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol. Psychiatry 59 (2006) 155-161
16. Sapolsky R.M., Zola-Morgan S., and Squire L.R. Inhibition of glucocorticoid secretion by the hippocampal formation in the primate. J. Neurosci. 11 (1991) 3695-3704
17. Ialenti A., Grassia G., Di Meglio P., Maffia P., Di Rosa M., and Ianaro A. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol. Pharmacol. 67 (2005) 1620-1628
18. L. Matthews, A. Berry, M. Tersigni, F. D'Acquisto, A. Ianaro, D. Ray, Thiazolidinediones are partial agonists for the glucocorticoid receptor, Endocrinology, (2008). [Epub ahead of print, doi: 10.1210/en.2008-0196].
19. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
20. Schiapparelli L., Simón A., Del Río J., and Frechilla D. Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: correlation with AMPA receptor subunit expression in rat hippocampus. Neuropharmacology 50 (2006) 897-907
21. Weiner M.F., Vobach S., Olsson K., Svetlik D., and Risser R.C. Cortisol secretion and Alzheimer's disease progression. Biol. Psychiatry 42 (1997) 1030-1038
22. Nichols N.R., Zieba M., and Bye N. Do glucocorticoids contribute to brain aging?. Brain Res. Rev. 37 (2001) 273-286
23. Green K.N., Billings L.M., Roozendaal B., McGaugh J.L., and LaFerla F.M. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci. 26 (2006) 9047-9056
24. Jeong Y.H., Park C.H., Yoo J., Shin K.Y., Ahn S.M., Kim H.S., Lee S.H., Emson P.C., and Suh Y.H. Chronic stress accelerates learning memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 20 (2006) 729-731
25. Sotiropoulos I., Catania C., Riedemann T., Fry J.P., Breen K.C., Michaelidis T.M., and Almeida O.F. Glucocorticoids trigger Alzheimer disease-like pathobiochemistry in rat neuronal cells expressing human tau. J. Neurochem. 107 (2008) 385-397
26. Jiang Q., Heneka M., and Landreth G.E. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 22 (2008) 1-14
27. Oitzl M.S., de Kloet E.R., Joels M., Schmid W., and Cole T.J. Spatial learning deficits in mice with a targeted glucocorticoid receptor gene disruption. Eur. J. Neurosci. 9 (1997) 2284-2296
28. De Kloet E.R., De Kock S., Schild V., and Veldhuis H.D. Antiglucocorticoid RU 38486 attenuates retention of a behaviour and disinhibits the hypothalamic-pituitary adrenal axis at different brain sites. Neuroendocrinology 47 (1988) 109-115
29. Woulfe J.M., Hammond R., Richardson B., Sooriabalan D., Parks W., Rippstein P., and Muñoz D.G. Reduction of neuronal intranuclear rodlets immunoreactive for tubulin and glucocorticoid receptor in Alzheimer's disease. Brain Pathol. 12 (2002) 300-307
30. Murphy E.K., Spencer R.L., Sipe K.J., and Herman J.P. Decrements in nuclear glucocorticoid receptor (GR) protein levels and DNA binding in aged rat hippocampus. Endocrinology 143 (2002) 1362-1370